Alzheimer's disease research, amyloid plaques, tau tangles, and cognitive decline
410 articles
A 19-year cohort study maps how amyloid and tau shift in CSF across the full Alzheimer spectrum, pinpointing the optimal intervention window.
From Alzheimer's to Parkinson's, a wave of novel FDA approvals is expanding treatment options for serious neurological conditions.
MIT researchers discovered that 30% of adult brain synapses are dormant but ready to activate, reshaping how we understand lifelong learning.
The EPICURO trial tests MERIVA® turmeric over 6 months to see if it protects cognition in adults with metabolic syndrome.
A liver enzyme released during exercise may rejuvenate brain blood vessels and protect against cognitive decline and Alzheimer's pathology.
A large UK Biobank study finds sleep duration, napping, and sleeplessness independently predict white matter damage tied to dementia risk.
A randomized study finds that disclosing financial compensation during recruitment calls lowered consent rates by up to 13 points in Alzheimer's research.
A Harvard-developed digital seed amplification assay can precisely quantify TDP-43 protein aggregates in CSF, offering a potential diagnostic breakthrough for frontotemporal dementia.
New research links excess astrocytic cholesterol to impaired brain clearance — a potential key mechanism driving Alzheimer's progression.
Arginine supplements reduced toxic amyloid buildup, brain inflammation, and behavioral decline in fly and mouse Alzheimer's models.
A roundup of recent FDA brain-health approvals including lecanemab's full Alzheimer's approval and a new glioma drug.
A memory clinic study finds 70% of patients tested positive for Alzheimer's pathology, with testing volumes exploding since new treatments arrived.
